Observational study on managing blood-related side effects in breast cancer targeted therapies
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
This study looks at how to manage blood-related side effects in breast cancer patients receiving targeted therapies to see what works best for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Not US/Canada) |
| Trial ID | NCT06503380 on ClinicalTrials.gov |
What this trial studies
This multicenter, real-world observational study aims to collect data on hematological toxicities associated with targeted therapies for breast cancer. It will involve both retrospective and prospective data collection from 1000 patients, focusing on treatment cycles N and N+1. The study will analyze disease characteristics and management strategies for hematological toxicity, considering factors such as age, cancer subtype, and treatment regimens. The research respects the medication choices of the participating clinicians.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed diagnosis of breast cancer who are receiving or have completed targeted therapies.
Not a fit: Patients who are pregnant or lactating, or those unable to provide informed consent, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of hematological toxicities in breast cancer patients undergoing targeted therapies.
How similar studies have performed: Other studies have shown success in managing hematological toxicities in cancer treatments, indicating that this approach has potential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * · The patients signed the informed consent and voluntarily participated in the study. * A definite diagnosis of any type of breast cancer. * Receiving or has completed targeted therapies. * Investigator judged that the patient need to receive or had received treatment or prevention for CTIT, CIN or CRA induced by targeted therapies. Exclusion Criteria: * · Pregnant or lactating women. * Failure to understand the study or to obtain informed consent. * The investigator determined other situations that are not suitable for inclusion.
Where this trial is running
Shanghai, Not US/Canada
- Zhi-Ming Shao — Shanghai, Not US/Canada, China (Recruiting)
Study contacts
- Principal investigator: Zhi-Ming Shao — Fudan University
- Study coordinator: Zhi-Ming Shao
- Email: zhi_ming_shao@163.com
- Phone: +86-021-64175590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.